作者
B Benzon, SG Zhao, MC Haffner, M Takhar, N Erho, K Yousefi, Paula Hurley, JL Bishop, J Tosoian, K Ghabili, M Alshalalfa, S Glavaris, BW Simons, P Tran, E Davicioni, RJ Karnes, K Boudadi, ES Antonarakis, EM Schaeffer, CG Drake, F Feng, AE Ross
发表日期
2017/3
期刊
Prostate cancer and prostatic diseases
卷号
20
期号
1
页码范围
28-35
出版商
Nature Publishing Group
简介
Background:
B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules, has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism of action remain unclear. B7-H3 protein expression correlates with prostate cancer outcomes, and humanized monoclonal antibodies (that is, enoblituzumab) are currently being investigated for therapeutic use. Here we used genomic expression data to examine the relationship between B7-H3 mRNA expression and prostate cancer.
Methods:
Prostatectomy tissue from 2781 patients were profiled using the Affymetrix HuEx 1.0 ST microarray. Pairwise comparisons were used to identify significant associations between B7-H3 expression and clinicopathologic variables, and survival analyses were used to evaluate the prognostic significance of B7-H3. Pearson’s correlation analyses were performed to assess the relationship of B7-H3 …
学术搜索中的文章
B Benzon, SG Zhao, MC Haffner, M Takhar, N Erho… - Prostate cancer and prostatic diseases, 2017